216 related articles for article (PubMed ID: 17565154)
1. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Garfield DH; Hercbergs A; Davis PJ
J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
[No Abstract] [Full Text] [Related]
2. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
3. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
4. Unanswered questions regarding the management of sunitinib-induced hypothyroidism.
Garfield D; Hercbergs A; Davis P
Nat Clin Pract Oncol; 2007 Dec; 4(12):674. PubMed ID: 17955044
[No Abstract] [Full Text] [Related]
5. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
6. How does sunitinib cause hypothyroidism?
Hershman JM; Liwanpo L
Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
[No Abstract] [Full Text] [Related]
7. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
8. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Feldt S; Schüssel K; Quinzler R; Franzmann A; Czeche S; Ludwig WD; Schulz M
Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
[TBL] [Abstract][Full Text] [Related]
9. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Clemons J; Gao D; Naam M; Breaker K; Garfield D; Flaig TW
Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
[TBL] [Abstract][Full Text] [Related]
10. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Sella A; Hercbergs AH; Hanovich E; Kovel S
Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
[TBL] [Abstract][Full Text] [Related]
11. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib induces hypothyroidism with a markedly reduced vascularity.
Makita N; Miyakawa M; Fujita T; Iiri T
Thyroid; 2010 Mar; 20(3):323-6. PubMed ID: 20187785
[TBL] [Abstract][Full Text] [Related]
13. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib and hypothyroidism.
Wolter P; Dumez H; Schöffski P
N Engl J Med; 2007 Apr; 356(15):1580; author reply 1580-1. PubMed ID: 17429091
[No Abstract] [Full Text] [Related]
15. [The safety and efficacy of sunitinib using a modified regimen (2 weeks on/1 week off) for treatment of metastatic renal cell carcinoma].
Togo Y; Shimatani K; Hanasaki T; Yo T; Nakanishi Y; Nagasawa S; Hashimoto T; Shiraishi Y; Taoka R; Suzuki T; Go S; Higuchi Y; Kanematsu A; Nojima M; Tsuchihashi K; Makino Y; Shimizu Y; Kanamaru S; Kono Y; Matsumoto K; Utsunomiya N; Ito N; Kawakita M; Yamamoto S
Hinyokika Kiyo; 2014 May; 60(5):209-14. PubMed ID: 24894855
[TBL] [Abstract][Full Text] [Related]
16. A Rare Case of Sunitinib-Induced Hyperammonemic Encephalopathy and Hypothyroidism in Metastatic Renal Cell Carcinoma.
Pilanc KN; Elbüken F; Ordu Ç; Köksal G; Tekelioğlu MH; Okutur K; Göksel S; Köksal Ü; Akçal T; Tecimer C
Am J Ther; 2016; 23(2):e583-7. PubMed ID: 24901901
[TBL] [Abstract][Full Text] [Related]
17. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
[TBL] [Abstract][Full Text] [Related]
18. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
Yıldız I; Varol U; Şen F; Kılıç L
Anadolu Kardiyol Derg; 2014 Nov; 14(7):654-6. PubMed ID: 25163084
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
20. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
[No Abstract] [Full Text] [Related]
[Next] [New Search]
